Daesung Microbiological Labs
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Daesung Microbiological Labs makes microbiological and related health-care products, biological preparations used in medical, veterinary, or laboratory settings.
It supplies these products to customers in the health-care sector and is listed on KOSDAQ, South Korea's technology and small-cap stock exchange. The company has consolidated subsidiaries, indicating it operates as a group with more than one business entity.
Summary is AI-generated and may contain errors · figures from DART filings
Daesung Microbiological Labs in five facts
What does Daesung Microbiological Labs do?
Daesung Microbiological Labs makes microbiological and related health-care products, biological preparations used in medical, veterinary, or laboratory settings.
Where is Daesung Microbiological Labs listed and in which sector?
Daesung Microbiological Labs (Korean name: 대성미생물) trades under KRX code 036480 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Daesung Microbiological Labs?
Its market capitalisation was US$16.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Daesung Microbiological Labs's latest annual revenue and operating profit?
For fiscal year 2025, Daesung Microbiological Labs reported revenue of US$19.6M, an operating loss of US$286.3K and a net loss of US$286.3K, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was up 9.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Supply contract signed
Daesung Microbiological Labs updated a previously disclosed supply contract with the Public Procurement Service, now worth US$1.19M, about 6.81% of its recent annual revenue, running through Sep 2026.
Supply contract · Sep 30 - [Amended] Change of largest shareholderOwnership change · Mar 25 · 2 versions
- Share transfer agreement that will change the largest shareholder
Daesung Microbiological Labs's controlling stake is set to change hands from an individual and 1 other to Insilico Co., Ltd., in a deal worth US$10.9M.
Ownership change · Mar 9 - [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Daesung Microbiological Labs updated its previously filed separate results for FY2025: revenue of US$17.6M (+9.1% year on year), operating profit of US$483K (from a loss a year earlier) and net income of US$404K (from a loss a year earlier).
Earnings · Mar 6 · 2 versions - Cash/in-kind dividend decision
Daesung Microbiological Labs declared a cash dividend of US$0.05 per share.
Dividend · Feb 4